标题
Preclinical and clinical development of palbociclib and future perspectives
作者
关键词
Cyclin, Cell cycle, Anti-tumor, Breast cancer, PI3K, Palbociclib, Cyclin-dependent kinases, CDK4/6
出版物
Clinical & Translational Oncology
Volume -, Issue -, Pages -
出版商
Springer Nature
发表日期
2018-03-21
DOI
10.1007/s12094-018-1850-3
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
- (2016) Hope S. Rugo et al. JOURNAL OF CLINICAL ONCOLOGY
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
- (2016) Massimo Cristofanilli et al. LANCET ONCOLOGY
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanistic Investigation of Bone Marrow Suppression Associated with Palbociclib and its Differentiation from Cytotoxic Chemotherapies
- (2015) W. Hu et al. CLINICAL CANCER RESEARCH
- Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer
- (2015) S. E. Wardell et al. CLINICAL CANCER RESEARCH
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
- (2015) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions
- (2014) Agnieszka K Witkiewicz et al. BREAST CANCER RESEARCH
- CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
- (2014) A. DeMichele et al. CLINICAL CANCER RESEARCH
- Modification of the DNA Damage Response by Therapeutic CDK4/6 Inhibition
- (2012) Jeffry L. Dean et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy
- (2012) Patrick J. Roberts et al. JNCI-Journal of the National Cancer Institute
- Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
- (2012) C. E. Caldon et al. MOLECULAR CANCER THERAPEUTICS
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)
- (2011) G K Schwartz et al. BRITISH JOURNAL OF CANCER
- Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
- (2011) K. T. Flaherty et al. CLINICAL CANCER RESEARCH
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I Study of PD 0332991, a Novel, Oral, Cyclin-D Kinase (CDK) 4/6 Inhibitor in Combination with Letrozole, for First-Line Treatment of Metastatic Post-Menopausal, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer.
- (2010) R. Finn et al. CANCER RESEARCH
- Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
- (2010) J L Dean et al. ONCOGENE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now